Cargando…

A novel Plasmodium vivax vaccine based on recombinant chimpanzee adenovirus ChAd63 and MVA expressing TRAP

Detalles Bibliográficos
Autores principales:	Bauza, Karolis, Billker, Oliver, Hill, Adrian VS, Reyes-Sandoval, Arturo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472262/ http://dx.doi.org/10.1186/1475-2875-11-S1-O49

Ejemplares similares

Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
por: Mensah, Victorine, et al.
Publicado: (2014)

Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites
por: Bauza, Karolis, et al.
Publicado: (2014)

Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children
por: Bowyer, Georgina, et al.
Publicado: (2014)

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants
por: Afolabi, Muhammed O, et al.
Publicado: (2016)

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal
por: Mensah, Victorine A., et al.
Publicado: (2016)

Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults
por: Ogwang, Caroline, et al.
Publicado: (2013)

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
por: O’Hara, Geraldine A., et al.
Publicado: (2012)

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
por: Tiono, Alfred B., et al.
Publicado: (2018)

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
por: Rampling, Tommy, et al.
Publicado: (2018)

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial
por: de Graaf, Hans, et al.
Publicado: (2021)

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals
por: Hodgson, Susanne H., et al.
Publicado: (2015)

Evaluation of Chimpanzee Adenovirus and MVA Expressing TRAP and CSP from Plasmodium cynomolgi to Prevent Malaria Relapse in Nonhuman Primates
por: Kim, Young Chan, et al.
Publicado: (2020)

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors
por: Sheehy, Susanne H., et al.
Publicado: (2012)

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
por: Morter, Richard, et al.
Publicado: (2022)

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection
por: Elias, Sean C, et al.
Publicado: (2014)

A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS
por: de Barra, Eoghan, et al.
Publicado: (2014)

Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure
por: Biswas, Sumi, et al.
Publicado: (2014)

Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses
por: Rollier, Christine S., et al.
Publicado: (2016)

Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity
por: Reyes-Sandoval, Arturo, et al.
Publicado: (2012)

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
por: Dicks, Matthew D. J., et al.
Publicado: (2015)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
por: Berg, Adam, et al.
Publicado: (2021)

Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients: A multicenter prospective observational study
por: Haase, Michael, et al.
Publicado: (2022)

Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan
por: Younis, Brima M., et al.
Publicado: (2021)

Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
por: Ewer, Katie J., et al.
Publicado: (2013)

Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors
por: Atcheson, Erwan, et al.
Publicado: (2018)

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults
por: Green, C, et al.
Publicado: (2023)

Aerosol Inhalation of Chimpanzee Adenovirus Vectors (ChAd68) Expressing Ancestral or Omicron BA.1 Stabilized Pre–Fusion Spike Glycoproteins Protects Non–Human Primates against SARS-CoV-2 Infection
por: Wang, Shen, et al.
Publicado: (2023)

A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH
por: Osman, Mohamed, et al.
Publicado: (2017)

Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1
por: Patel, Shreena Umit, et al.
Publicado: (2021)

Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice
por: Warimwe, George M, et al.
Publicado: (2013)

LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis
por: Lacey, Charles, et al.
Publicado: (2022)

Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle
por: Dulal, Pawan, et al.
Publicado: (2016)

Nonclinical safety assessment of repeated administration and biodistribution of ChAd3‐EBO‐Z Ebola candidate vaccine
por: Planty, Camille, et al.
Publicado: (2020)

Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs
por: Finch, Courtney L., et al.
Publicado: (2022)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
por: Beavis, Ashley C., et al.
Publicado: (2023)

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01(B) With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP
por: Rampling, Tommy, et al.
Publicado: (2016)

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
por: Ahmed, T, et al.
Publicado: (2012)

Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults
por: Green, Christopher A., et al.
Publicado: (2019)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
por: Zhang, Cheng, et al.
Publicado: (2023)

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
por: Alharbi, Naif Khalaf, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b5mq71l6qc9b1rd7qo690qk499